Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib
Authors
Keywords
-
Journal
ACTA PHARMACOLOGICA SINICA
Volume 32, Issue 3, Pages 399-407
Publisher
Springer Nature
Online
2011-03-04
DOI
10.1038/aps.2010.218
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cytochrome P450-Mediated Bioactivation of the Epidermal Growth Factor Receptor Inhibitor Erlotinib to a Reactive Electrophile
- (2010) X. Li et al. DRUG METABOLISM AND DISPOSITION
- Identification and Characterization of Human UDP-Glucuronosyltransferases Responsible for the In Vitro Glucuronidation of Daphnetin
- (2010) S. C. Liang et al. DRUG METABOLISM AND DISPOSITION
- Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction
- (2009) Zhong-Ze Fang et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Clinical pharmacokinetics of tyrosine kinase inhibitors
- (2009) Nielka P. van Erp et al. CANCER TREATMENT REVIEWS
- Bioactivation of the Epidermal Growth Factor Receptor Inhibitor Gefitinib: Implications for Pulmonary and Hepatic Toxicities
- (2009) Xiaohai Li et al. CHEMICAL RESEARCH IN TOXICOLOGY
- Comparison of the Drug-Drug Interactions Potential of Erlotinib and Gefitinib via Inhibition of UDP-Glucuronosyltransferases
- (2009) Y. Liu et al. DRUG METABOLISM AND DISPOSITION
- The Conduct of in Vitro Studies to Address Time-Dependent Inhibition of Drug-Metabolizing Enzymes: A Perspective of the Pharmaceutical Research and Manufacturers of America
- (2009) S. W. Grimm et al. DRUG METABOLISM AND DISPOSITION
- Comparison of Different Algorithms for Predicting Clinical Drug-Drug Interactions, Based on the Use of CYP3A4 in Vitro Data: Predictions of Compounds as Precipitants of Interaction
- (2009) O. A. Fahmi et al. DRUG METABOLISM AND DISPOSITION
- Characterization of Dasatinib and Its Structural Analogs as CYP3A4 Mechanism-Based Inactivators and the Proposed Bioactivation Pathways
- (2009) X. Li et al. DRUG METABOLISM AND DISPOSITION
- Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma
- (2009) Fabienne Thomas et al. EUROPEAN JOURNAL OF CANCER
- Quantitative structure-retention relationship studies for taxanes including epimers and isomeric metabolites in ultra fast liquid chromatography
- (2009) Pei-Pei Dong et al. JOURNAL OF CHROMATOGRAPHY A
- C-7 configuration as one of determinants in taxanes metabolism by human cytochrome P450 enzymes
- (2009) Y.-Y. Zhang et al. XENOBIOTICA
- A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers
- (2008) P A Vasey et al. BRITISH JOURNAL OF CANCER
- Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors
- (2008) Chia-Chi Lin et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor
- (2008) S. Harmsen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Rhabdomyolysis Resulting from Pharmacologic Interaction Between Erlotinib and Simvastatin
- (2008) Muthu Veeraputhiran et al. Clinical Lung Cancer
- Comparative Analysis of CYP3A Heteroactivation by Steroid Hormones and Flavonoids in Different in Vitro Systems and Potential in Vivo Implications
- (2008) J. Henshall et al. DRUG METABOLISM AND DISPOSITION
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now